The microeconomics of personalized medicine: today's challenge and tomorrow's promise, Nature Reviews Drug Discovery, vol.295, issue.4, pp.279-286, 2009. ,
DOI : 10.1038/nrd2825
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs, Am J Manag Care, vol.10, issue.7, pp.425-432, 2004. ,
Pharmacogenetics in Oncology: A Promising Field, Current Pharmaceutical Design, vol.16, issue.2, pp.155-163, 2010. ,
DOI : 10.2174/138161210790112719
Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes, PharmacoEconomics, vol.44, issue.12, pp.569-587, 2008. ,
DOI : 10.2165/00019053-200826070-00005
Pharmacogenomics, Evidence, and the Role of Payers, Public Health Genomics, vol.12, issue.3, pp.149-157, 2009. ,
DOI : 10.1159/000189627
Methods for the economic evaluation of health care programs. Second Edition, 1997. ,
Distinguishing Product and Practice Regulation in Personalized Medicine, Clinical Pharmacology & Therapeutics, vol.3, issue.2, pp.288-293530, 2002. ,
DOI : 10.1038/sj.clpt.6100042
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002. ,
DOI : 10.1056/NEJMoa021967
Gene Expression Profiling and Clinical Outcome in Breast Cancer, OMICS: A Journal of Integrative Biology, vol.10, issue.4, pp.429-443, 2006. ,
DOI : 10.1089/omi.2006.10.429
Estimates of cancer incidence and mortality in Europe in 1995, European Journal of Cancer, vol.38, issue.1, pp.99-166, 2002. ,
DOI : 10.1016/S0959-8049(01)00350-1
Adjuvant chemotherapy in 2005: Standards and beyond, The Breast, vol.14, issue.6, pp.439-445, 2005. ,
DOI : 10.1016/j.breast.2005.08.004
Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, Journal of Clinical Oncology, vol.23, issue.16, pp.3686-3696, 2005. ,
DOI : 10.1200/JCO.2005.10.517
Adjuvant Docetaxel for Node-Positive Breast Cancer, New England Journal of Medicine, vol.352, issue.22, pp.2302-2313, 2005. ,
DOI : 10.1056/NEJMoa043681
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, Journal of Clinical Oncology, vol.24, issue.36, pp.5664-5671, 2006. ,
DOI : 10.1200/JCO.2006.07.3916
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial, Clin Cancer Res, vol.8, issue.5, pp.1073-1079, 2002. ,
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients, Cancer, vol.106, issue.11, pp.2337-2344, 2006. ,
Taxanes in adjuvant breast cancer setting: Which standard in Europe?, Critical Reviews in Oncology/Hematology, vol.55, issue.3, pp.167-175, 2005. ,
DOI : 10.1016/j.critrevonc.2005.04.003
Assessing the cost-effectiveness of pharmacogenomics, AAPS PharmSci, vol.2, issue.3, p.29, 2000. ,
DOI : 10.1208/ps020329
The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics, PharmacoEconomics, vol.57, issue.9, pp.481-493, 2004. ,
DOI : 10.2165/00019053-200422080-00001
Genomic Medicine ??? A Primer, New England Journal of Medicine, vol.347, issue.19, pp.1512-1520, 2002. ,
DOI : 10.1056/NEJMra012240
Gene expression profiles of poor-prognosis primary breast cancer correlate with survival, Human Molecular Genetics, vol.11, issue.8, pp.863-872, 2002. ,
DOI : 10.1093/hmg/11.8.863
Gene expression profile predicts outcome after anthracyclinebased adjuvant chemotherapy in early breast cancer, Breast Cancer Res Treat, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00594464
Cost-effectiveness of adjuvant docetaxel for nodepositive breast cancer patients: results of the PACS 01 economic study, Ann Oncol, 2010. ,
The Distinction Between Cost and Charges, Annals of Internal Medicine, vol.96, issue.1, pp.102-109, 1982. ,
DOI : 10.7326/0003-4819-96-1-102
High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?, Breast Cancer Research, vol.4, issue.5, p.214, 2006. ,
DOI : 10.1186/bcr433
Pharmacogenomics: Challenges and Opportunities, Annals of Internal Medicine, vol.145, issue.10, pp.749-757, 2006. ,
DOI : 10.7326/0003-4819-145-10-200611210-00007
Translating Pharmacogenomics: Challenges on the Road to the Clinic, PLoS Medicine, vol.12, issue.8, p.209, 2007. ,
DOI : 10.1371/journal.pmed.0040209.t004
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer, The Oncologist, vol.13, issue.5, pp.477-493, 2008. ,
DOI : 10.1634/theoncologist.2007-0248
Gene Expression Profile Assays as Predictors of Recurrence-Free Survival in Early-Stage Breast Cancer: A Metaanalysis, Clinical Breast Cancer, vol.7, issue.5, pp.372-379, 2006. ,
DOI : 10.3816/CBC.2006.n.053
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogenreceptor-positive , early-stage breast cancer, Am J Manag Care, vol.11, issue.5, pp.313-324, 2005. ,
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer, Cancer, vol.7, issue.6, pp.1011-1018, 2007. ,
DOI : 10.1002/cncr.22506
Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?, Genetics in Medicine, vol.18, issue.6, pp.380-389, 2005. ,
DOI : 10.1097/01.GIM.0000170776.31248.75
One-Way Essential Complements, SSRN Electronic Journal, vol.1588, 2006. ,
DOI : 10.2139/ssrn.937384
On price competition with complementary goods, Economics Letters, vol.70, issue.3, pp.431-437, 2001. ,
DOI : 10.1016/S0165-1765(00)00383-9
Willingness to Pay for a Quality-adjusted Life Year, Medical Decision Making, vol.336, issue.3, pp.332-342, 2000. ,
DOI : 10.1177/0272989X0002000310
Trying to estimate a monetary value for the QALY, Journal of Health Economics, vol.28, issue.3, pp.553-562, 2009. ,
DOI : 10.1016/j.jhealeco.2009.02.003
Modelling the monetary value of a QALY: a new approach based on UK data, Health Economics, vol.375, issue.1, pp.933-950, 2009. ,
DOI : 10.1002/hec.1416